These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16272649)

  • 1. [Effect of vitamin D on remaining kidney function after chronic kidney failure in preservation period patient].
    Inaguma D; Tatematsu M; Shinjo H; Suzuki S; Mishima T; Inaba S; Nakamura T; Kato T
    Clin Calcium; 2005 Sep; 15 Suppl 1():152-5; discussion 155. PubMed ID: 16272649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-alpha-OH-cholecalciferol (1-alpha-OHD3) and low phosphate diet in predialysis chronic renal failure: effects on renal function and on secondary hyperparathyroidism.
    Coen G; Messa F; Massimetti C; Mazzaferro S; Manganiello M; Donato G; Finistauri D; Giuliano G; Cinotti GA
    Acta Vitaminol Enzymol; 1984; 6(2):129-35. PubMed ID: 6496255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of secondary hyperparathyroidisms of predialysis chronic renal failure with low doses of 1.25(OH)2D3].
    Kato N; Kasai K; Kawaguchi Y; Yamamoto H; Shigematu T; Sakai O
    Nihon Jinzo Gakkai Shi; 1995 Oct; 37(10):543-8. PubMed ID: 7474506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
    Okada K; Nagura Y; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
    Koskimies O; Ala-Houhala M
    Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
    Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of 1,25-dihydroxyvitamin D3 in early renal failure.
    Goodman WG; Coburn JW
    Annu Rev Med; 1992; 43():227-37. PubMed ID: 1580587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
    Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
    Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of secondary hyperparathyroidism with vitamin D metabolites].
    Stojimirović B; Pejanović S; Djukanović Lj
    Srp Arh Celok Lek; 1994; 122(7-8):197-9. PubMed ID: 17974384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment options in secondary renal hyperparathyroidism.
    Reichel H
    Nephrol Dial Transplant; 2006 Jan; 21(1):23-8. PubMed ID: 16144852
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronotherapy of high-dose 1,25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study.
    Tsuruoka S; Sugimoto K; Ohmori M; Kawaguchi A; Saito T; Fujimura A
    Clin Pharmacol Ther; 1999 Dec; 66(6):609-16. PubMed ID: 10613617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
    Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
    Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term therapy with calcitriol in patients with moderate renal failure.
    Healy MD; Malluche HH; Goldstein DA; Singer FR; Massry SG
    Arch Intern Med; 1980 Aug; 140(8):1030-3. PubMed ID: 6893118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.